Table 2.

Indications for performing 25-Hydroxy vitamin D testing across age ranges

IndicationaAll (%)75+ (%)60–74.9 (%)30–59.9 (%)<30 (%)
Appropriate
Potent antiresorptive agenta176 (1.0)102 (2.2)58 (1.3)16 (0.2)0
Suspected osteomalaciab3315 (19.0)751 (16.4)876 (20.0)1373 (20.5)315 (18.3)
Malabsorptionc331 (1.9)119 (2.6)116 (2.6)184 (2.7)55 (3.2)
Epilepsy treatmentd85 (0.5)7 (0.2)23 (0.5)47 (0.7)8 (0.5)
Total %22.421.324.524.222.0
Uncertain
Fallse593 (3.4)441 (9.6)107 (2.4)41 (0.6)4 (0.2)
Osteoporosisf645 (3.7)506 (11.0)280 (6.4)242 (3.6)17 (1.0)
Total %7.120.68.84.21.2
Inappropriate (common examples)
Non-specific symptomsg4492 (26.9)859 (18.7)926 (21.1)2248 (33.5)652 (37.9)
Proceduralh3308 (19.0)1120 (24.4)899 (20.5)1048 (15.6)241 (14.0)
Neuropsychiatrici503 (2.9)254 (5.5)69 (1.6)137 (2.0)43 (2.5)
Total (excluding appropriate and uncertain indications) %70.458.166.771.676.8
  • aStarting on zoledronate or denosumab. bAbnormal calcium or alkaline phosphatase, pain, ache, cramp, myopathy, weakness, mobility or gait disorder. cDiarrhoea, coeliac disease, Crohn's disease, inflammatory bowel disease, cystic fibrosis or gastric bypass. dEpilepsy, valproate, phenytoin, phenobarbital or carbamazepine. eFall, syncope or collapse. fSuspected osteoporosis, fracture, ‘bone screen’ or perioperative period. gTired, fatigue, malaise, exhaustion, ‘off-legs’, general decline, frailty, dizziness, weight loss, sarcopenia, urinary tract infection, pyrexia. hRoutine, screen, review, recheck, repeat, admission, monitor or requested by someone else. iDementia, delirium, confusion, mood disorder or depression.